On the number of tetrahedra with minimum, unit, and distinct volumes in three-space

We formulate and give partial answers to several combinatorial problems on volumes of simplices determined by $n$ points in 3-space, and in general in $d$ dimensions. (i) The number of tetrahedra of minimum (nonzero) volume spanned by $n$ points in \RR^3 is at most ${2/3}n^3-O(n^2)$, and there are point sets for which this number is ${3/16}n^3-O(n^2)$. We also present an $O(n^3)$ time algorithm for reporting all tetrahedra of minimum nonzero volume, and thereby extend an algorithm of Edelsbrunner, O'Rourke, and Seidel. In general, for every k,d\in \NN, $1\leq k \leq d$, the maximum number of $k$-dimensional simplices of minimum (nonzero) volume spanned by $n$ points in \RR^d is $\Theta(n^k)$. (ii) The number of unit-volume tetrahedra determined by $n$ points in \RR^3 is $O(n^{7/2})$, and there are point sets for which this number is $\Omega(n^3 \log \log{n})$. (iii) For every d\in \NN, the minimum number of distinct volumes of all full-dimensional simplices determined by $n$ points in \RR^d, not all on a hyperplane, is $\Theta(n)$.Comment: 19 pages, 3 figures, a preliminary version has appeard in proceedings of the ACM-SIAM Symposium on Discrete Algorithms, 200

Cutting Polygons into Small Pieces with Chords: Laser-Based Localization

Motivated by indoor localization by tripwire lasers, we study the problem of cutting a polygon into small-size pieces, using the chords of the polygon. Several versions are considered, depending on the definition of the "size" of a piece. In particular, we consider the area, the diameter, and the radius of the largest inscribed circle as a measure of the size of a piece. We also consider different objectives, either minimizing the maximum size of a piece for a given number of chords, or minimizing the number of chords that achieve a given size threshold for the pieces. We give hardness results for polygons with holes and approximation algorithms for multiple variants of the problem

Stable Electron Beams With Low Absolute Energy Spread From a LaserWakefield Accelerator With Plasma Density Ramp Controlled Injection

Laser wakefield accelerators produce accelerating gradientsup to hundreds of GeV/m, and recently demonstrated 1-10 MeV energy spreadat energies up to 1 GeV using electrons self-trapped from the plasma.Controlled injection and staging may further improve beam quality bycircumventing tradeoffs between energy, stability, and energyspread/emittance. We present experiments demonstrating production of astable electron beam near 1 MeV with hundred-keV level energy spread andcentral energy stability by using the plasma density profile to controlselfinjection, and supporting simulations. Simulations indicate that suchbeams can be post accelerated to high energies,potentially reducingmomentum spread in laser acceleratorsby 100-fold or more

Nesfatin-1/NUCB2 as a Potential New Element of Sleep Regulation in Rats.

STUDY OBJECTIVES: Millions suffer from sleep disorders that often accompany severe illnesses such as major depression; a leading psychiatric disorder characterized by appetite and rapid eye movement sleep (REMS) abnormalities. Melanin-concentrating hormone (MCH) and nesfatin-1/NUCB2 (nesfatin) are strongly co - expressed in the hypothalamus and are involved both in food intake regulation and depression. Since MCH was recognized earlier as a hypnogenic factor, we analyzed the potential role of nesfatin on vigilance. DESIGN: We subjected rats to a 72 h-long REMS deprivation using the classic flower pot method, followed by a 3 h-long 'rebound sleep'. Nesfatin mRNA and protein expressions as well as neuronal activity (Fos) were measured by quantitative in situ hybridization technique, ELISA and immunohistochemistry, respectively, in 'deprived' and 'rebound' groups, relative to controls sacrificed at the same time. We also analyzed electroencephalogram of rats treated by intracerebroventricularly administered nesfatin-1, or saline. RESULTS: REMS deprivation downregulated the expression of nesfatin (mRNA and protein), however, enhanced REMS during 'rebound' reversed this to control levels. Additionally, increased transcriptional activity (Fos) was demonstrated in nesfatin neurons during 'rebound'. Centrally administered nesfatin-1 at light on reduced REMS and intermediate stage of sleep, while increased passive wake for several hours and also caused a short-term increase in light slow wave sleep. CONCLUSIONS: The data designate nesfatin as a potential new factor in sleep regulation, which fact can also be relevant in the better understanding of the role of nesfatin in the pathomechanism of depression

26th Annual Computational Neuroscience Meeting (CNS*2017): Part 3 - Meeting Abstracts - Antwerp, Belgium. 15–20 July 2017

This work was produced as part of the activities of FAPESP Research,\ud Disseminations and Innovation Center for Neuromathematics (grant\ud 2013/07699-0, S. Paulo Research Foundation). NLK is supported by a\ud FAPESP postdoctoral fellowship (grant 2016/03855-5). ACR is partially\ud supported by a CNPq fellowship (grant 306251/2014-0)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Equilibria and Selfish Behavior in Peer Matching

Peer to peer networks are distributed data-sharing systems without a centralized infrastructure

The k Most Frequent Distances in the Plane

A new upper bound is shown for the number of incidences between n points and n families of concentric circles in the plane. As a consequence, it is shown that the number of the k most frequent distances among n points in the plane is fn (k) = O(n ) improving earlier bound of Akatsu, Tamaki, and Tokuyama